Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reissued by stock analysts at J P Morgan Chase & Co in a report released on Thursday.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and issued a $82.00 target price on shares of Sage Therapeutics in a research note on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $90.00 target price on shares of Sage Therapeutics in a research note on Friday, July 14th. Needham & Company LLC started coverage on shares of Sage Therapeutics in a research note on Monday, May 15th. They issued a “buy” rating and a $82.00 target price for the company. Finally, Bank of America Corporation started coverage on shares of Sage Therapeutics in a research note on Friday, May 12th. They issued a “buy” rating and a $85.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $89.64.

Shares of Sage Therapeutics (SAGE) opened at 87.00 on Thursday. The firm has a 50 day moving average price of $82.39 and a 200-day moving average price of $73.76. Sage Therapeutics has a 12 month low of $36.86 and a 12 month high of $90.43. The firm’s market cap is $3.26 billion.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by $0.25. During the same quarter in the prior year, the company posted ($1.08) earnings per share. On average, analysts predict that Sage Therapeutics will post ($7.38) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/sage-therapeutics-inc-sage-rating-reiterated-by-j-p-morgan-chase-co/1537203.html.

A number of large investors have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Sage Therapeutics by 10,082.5% in the first quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock valued at $203,482,000 after buying an additional 2,835,006 shares during the period. MARSHALL WACE ASIA Ltd bought a new stake in shares of Sage Therapeutics during the first quarter valued at about $35,493,000. Marshall Wace North America L.P. bought a new stake in shares of Sage Therapeutics during the first quarter valued at about $35,493,000. Point72 Asset Management L.P. increased its stake in shares of Sage Therapeutics by 512.9% in the first quarter. Point72 Asset Management L.P. now owns 395,300 shares of the biopharmaceutical company’s stock valued at $28,094,000 after buying an additional 330,800 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Sage Therapeutics by 10.8% in the first quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after buying an additional 261,759 shares during the period.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.